The overall purpose of Core A is to provide a central structure to support the conduct of each of the three highly interrelated projects comprising this program project grant and also to Cores B and C. Core A supports administrative, regulatory, data management and statistical functions for all three projects as well as facilitating interactions with internal and external consultants to assure optimal scientific progress.
Specific Aims of Core A To provide administrative services and infrastructure (meeting scheduling, preparation of progress reports and manuscripts, budgeting, subcontract management, patient care budget development and monitoring, etc.) for Projects 1, 2, and 3 and Cores B and C. To provide regulatory services (protocol and IND preparation, IRB interactions, etc.) for Projects 1, 2 and 3 and Cores B and C. To provide centralized data management support for all protocols in Projects 1, 2, and 3. To provide biostatistical support for all protocols in Projects 1, 2, and 3. To provide internal and external advisory board consultation to assess the progress and direction of Projects 1, 2, and 3 and Cores B and C. To coordinate centralized Flow Cytometry and Molecular Diagnostic Testing for Biomarkers for Projects 1, 2, and 3. Core A provides equal levels of support to Projects 1, 2, and 3 (and also supplies administrative support to Cores B and C).

Public Health Relevance

The overall objective of this Program Project Grant is to improve the outcome of patients with hematologic malignancies by developing curative strategies using radiolabeled monoclonal antibodies in the setting of hematopoietic cell transplantation. This global Specific Aim will be pursued in three interactive, complementary projects that require a smoothly functioning administrative infrastructure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA044991-25
Application #
8546160
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
25
Fiscal Year
2013
Total Cost
$425,610
Indirect Cost
$117,324
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Green, Damian J; O'Steen, Shyril; Lin, Yukang et al. (2018) CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood 131:611-620
Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607
Greenbaum, Adam M; Green, Damian J; Holmberg, Leona A et al. (2018) Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. Blood Res 53:223-226
Green, Damian J; Press, Oliver W (2017) Whither Radioimmunotherapy: To Be or Not To Be? Cancer Res 77:2191-2196
O'Steen, Shyril; Green, Damian J; Gopal, Ajay K et al. (2017) Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Res 77:3885-3893
Cowan, Andrew J; Stevenson, Phillip A; Gooley, Ted A et al. (2017) Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. Br J Haematol 176:583-590
Cowan, Andrew J; Stevenson, Philip A; Cassaday, Ryan D et al. (2016) Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. Biol Blood Marrow Transplant 22:380-385
Green, D J; Bensinger, W I; Holmberg, L A et al. (2016) Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 51:1330-1336
Shadman, Mazyar; Gopal, Ajay K; Kammerer, Britt et al. (2016) Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission. Leuk Lymphoma 57:572-6
Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19

Showing the most recent 10 out of 133 publications